| scholarly article | Q13442814 |
| P356 | DOI | 10.1056/NEJMOA0706135 |
| P698 | PubMed publication ID | 18256392 |
| P50 | author | Elizabeth J. Phillips | Q91133566 |
| Simon A. Mallal | Q91272953 | ||
| Jean-Michel Molina | Q108298727 | ||
| P2093 | author name string | Oleg Kozyrev | |
| David Nolan | |||
| Sara Hughes | |||
| Phillip Hay | |||
| Janez Tomazic | |||
| Giampiero Carosi | |||
| Eva Jägel-Guedes | |||
| Cassy Workman | |||
| Arlene Hughes | |||
| Sorin Rugina | |||
| Alastair Benbow | |||
| Daren Thorborn | |||
| Juan Flores Cid | |||
| Nicholas Fitch | |||
| PREDICT-1 Study Team | |||
| Susanna Ryan | |||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | abacavir | Q304330 |
| P304 | page(s) | 568-579 | |
| P577 | publication date | 2008-02-01 | |
| P1433 | published in | The New England Journal of Medicine | Q582728 |
| P1476 | title | HLA-B*5701 screening for hypersensitivity to abacavir. | |
| P478 | volume | 358 |
| Q28711804 | 'Sifting the significance from the data' - the impact of high-throughput genomic technologies on human genetics and health care |
| Q34792068 | A Genome-Wide Screen for Large-Effect Alloimmunization Susceptibility Loci among Red Blood Cell Transfusion Recipients with Sickle Cell Disease |
| Q35023821 | A Prospective Screening of HLA-B*57.01 Allelic Variant for Preventing the Hypersensivity Reaction to Abacavir: Experience from the Laboratory of Molecular Biology of the Infectious Diseases Division at the University Hospital of Salerno |
| Q36423260 | A Review of the 2010 WHO Adult Antiretroviral Therapy Guidelines: Implications and Realities of These Changes for Zambia |
| Q38777644 | A Systematic Review of Economic Evaluations of Pharmacogenetic Testing for Prevention of Adverse Drug Reactions. |
| Q38826219 | A brighter future for the implementation of pharmacogenomic testing |
| Q34602508 | A call for accurate pharmacogenetic labeling: telling it like it is |
| Q24239831 | A combination drug of abacavir-lamivudine-zidovudine (Trizivir®) for treating HIV infection and AIDS |
| Q42868757 | A fluorescence-based sequence-specific primer PCR for the screening of HLA-B(*)57:01. |
| Q33419319 | A genome-wide association study of heparin-induced thrombocytopenia using an electronic medical record |
| Q42966589 | A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury |
| Q35783016 | A large candidate gene survey identifies the KCNE1 D85N polymorphism as a possible modulator of drug-induced torsades de pointes |
| Q34662516 | A novel Acute Retroviral Syndrome Severity Score predicts the key surrogate markers for HIV-1 disease progression |
| Q35321693 | A novel single cDNA amplicon pyrosequencing method for high-throughput, cost-effective sequence-based HLA class I genotyping |
| Q50518269 | A pragmatic randomized controlled trial of thiopurine methyltransferase genotyping prior to azathioprine treatment: the TARGET study. |
| Q38030496 | A rare but severe pulmonary side effect of cetuximab in two patients. |
| Q38085220 | A review of pharmacogenetics of adverse drug reactions in elderly people |
| Q34778565 | A review of the pharmacokinetics of abacavir |
| Q40092386 | A severe hypersensitivity reaction to abacavir following re-challenge |
| Q54204422 | A transgenic mouse model for HLA-B*57:01-linked abacavir drug tolerance and reactivity. |
| Q38836848 | A web resource for mining HLA associations with adverse drug reactions: HLA-ADR |
| Q34215820 | A whole-genome association study of major determinants for allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients |
| Q36370958 | A world allergy organization international survey on diagnostic procedures and therapies in drug allergy/hypersensitivity |
| Q38951349 | Abacavir + dolutegravir + lamivudine for the treatment of HIV. |
| Q58557819 | Abacavir Hypersensitivity Reaction Reporting Rates During a Decade of HLA-B*5701 Screening as a Risk Mitigation Measure |
| Q37636061 | Abacavir and lamivudine combination |
| Q37905058 | Abacavir and lamivudine for the treatment of human immunodeficiency virus |
| Q37095697 | Abacavir hypersensitivity reaction: an update |
| Q37353680 | Abacavir hypersensitivity: a model system for pharmacogenetic test adoption |
| Q35737682 | Abacavir increases platelet reactivity via competitive inhibition of soluble guanylyl cyclase |
| Q28538078 | Abacavir induced T cell reactivity from drug naïve individuals shares features of allo-immune responses |
| Q34140322 | Abacavir induces loading of novel self-peptides into HLA-B*57: 01: an autoimmune model for HLA-associated drug hypersensitivity |
| Q27008841 | Abacavir pharmacogenetics--from initial reports to standard of care |
| Q49037532 | Abacavir usage patterns and hypersensitivity reactions in the EuroSIDA cohort. |
| Q24235506 | Abacavir versus other nucleoside reverse transcriptase inhibitor (NRTI) backbone therapies for treatment of HIV infection |
| Q94348239 | Abacavir versus other nucleoside reverse transcriptase inhibitor (NRTI) backbone therapies for treatment of HIV infection |
| Q24202180 | Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV |
| Q40869976 | Abacavir-induced fulminant hepatic failure in a HIV/HCV co-infected patient |
| Q40394091 | Abacavir-induced reaction with fever and severe skin rash in a patient tested human leukocyte antigen-B*5701 negative |
| Q28543405 | Abacavir-reactive memory T cells are present in drug naïve individuals |
| Q33715435 | Abacavir/lamivudine combination in the treatment of HIV: a review. |
| Q35233168 | Abacavir/lamivudine fixed-dose combination antiretroviral therapy for the treatment of HIV. |
| Q35214141 | Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results |
| Q37803527 | Acceptance of biomarker-based tests for application in clinical practice: criteria and obstacles |
| Q44858073 | Accuracy of SNPs to predict risk of HLA alleles associated with drug-induced hypersensitivity events across racial groups |
| Q36802085 | Achieving the World Health Organization's vision for clinical pharmacology |
| Q57177440 | Active suppression rather than ignorance: tolerance to abacavir-induced HLA-B*57:01 peptide repertoire alteration |
| Q28547607 | Acyclovir Has Low but Detectable Influence on HLA-B*57:01 Specificity without Inducing Hypersensitivity |
| Q43190836 | Adding the 'medicines' back into personalized medicine to improve cancer treatment outcomes |
| Q38663764 | Advances in the Pharmacogenomics of Adverse Drug Reactions. |
| Q34594695 | Adverse cutaneous reactions associated with the newest antiretroviral drugs in patients with human immunodeficiency virus infection |
| Q38723580 | Adverse events associated with abacavir use in HIV-infected children and adolescents: a systematic review and meta-analysis |
| Q36242667 | Adversomics: a new paradigm for vaccine safety and design |
| Q69682607 | African Pharmacogenomics Consortium: Consolidating pharmacogenomics knowledge, capacity development and translation in Africa |
| Q38594891 | Allopurinol hypersensitivity: investigating the cause and minimizing the risk |
| Q58875252 | An Introduction to Pharmacogenomics and Personalized Medicine |
| Q37613520 | An Update on Drug-induced Liver Injury |
| Q35147717 | An assessment of adverse drug reactions among HIV positive patients receiving antiretroviral treatment in South Africa |
| Q48230747 | An effective strategy to prevent allopurinol-induced hypersensitivity by HLA typing. |
| Q45241984 | An evaluation of pharmacists' expectations towards pharmacogenomics |
| Q56888883 | Analysis of drug-drug interactions among patients receiving antiretroviral regimens using data from a large open-source prescription database |
| Q30999121 | Analyzing the potential for incorrect haplotype calls with different pharmacogenomic assays in different populations: a simulation based on 1000 Genomes data |
| Q57549163 | Antimicrobial Agents |
| Q37389754 | Antimicrobial stewardship's new weapon? A review of antibiotic allergy and pathways to 'de-labeling'. |
| Q37234729 | Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society-USA Panel |
| Q38111430 | Antiretroviral drug-related toxicities - clinical spectrum, prevention, and management. |
| Q38170576 | Antiretroviral regimens sparing agents from the nucleoside(tide) reverse transcriptase inhibitor class: a review of the recent literature |
| Q37910819 | Antiretroviral therapy 2010 update: current practices and controversies |
| Q37770721 | Antiretroviral therapy and management of HIV infection |
| Q35770848 | Antiretroviral therapy in Indian setting: when & what to start with, when & what to switch to? |
| Q33877347 | Antiretroviral therapy in the clinic |
| Q34085926 | Antiretroviral therapy: current drugs |
| Q81917671 | Antiretroviral therapy: when to start and which drugs to use |
| Q40470257 | Antiretroviral treatment for HIV infection: Swedish recommendations 2016. |
| Q37870932 | Antiretroviral use during pregnancy for treatment or prophylaxis |
| Q34075812 | Antiviral drug allergy. |
| Q46445488 | Applicability of pharmacogenetic studies in daily clinical practice |
| Q40186791 | Application of pharmacogenomics to investigate adverse drug reactions to the disease-modifying treatments for multiple sclerosis: a case-control study protocol for dimethyl fumarate-induced lymphopenia |
| Q26864747 | Application of routine electronic health record databases for pharmacogenetic research |
| Q47284170 | Applications of pharmacogenomics in regulatory science: a product life cycle review |
| Q37695437 | Approach to the diagnosis of drug hypersensitivity reactions: similarities and differences between Europe and North America. |
| Q38286229 | Are drug metabolites able to cause T-cell-mediated hypersensitivity reactions? |
| Q57697028 | Are health technology assessments of pharmacogenetic tests feasible? A case study ofCYP2D6testing in the treatment of breast cancer with tamoxifen |
| Q36998698 | Are randomized trials obsolete or more important than ever in the genomic era? |
| Q90461024 | Assessing the Implementation of Pharmacogenomic Panel-Testing in Primary Care in the Netherlands Utilizing a Theoretical Framework |
| Q37803526 | Assessing the clinical utility of diagnostics used in drug therapy |
| Q26783472 | Assessing value of innovative molecular diagnostic tests in the concept of predictive, preventive, and personalized medicine |
| Q40759624 | Assessment of pharmacogenetic tests: presenting measures of clinical validity and potential population impact in association studies |
| Q51055927 | Association between HLA-B*1301 and dapsone-induced hypersensitivity reactions among leprosy patients in China. |
| Q36723349 | Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study |
| Q47254975 | Association of CYP2C9*3 with phenytoin-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: A systematic review and meta-analysis |
| Q57557226 | Association of HLA-A*31:01 Screening With the Incidence of Carbamazepine-Induced Cutaneous Adverse Reactions in a Japanese Population |
| Q36740238 | Association of human leukocyte antigen alleles and nevirapine hypersensitivity in a Malawian HIV-infected population |
| Q34763589 | Association of pharmacogenetic markers with premature discontinuation of first-line anti-HIV therapy: an observational cohort study |
| Q91659814 | Associations between human leukocyte antigen polymorphisms and hypersensitivity to antiretroviral therapy in patients with human immunodeficiency virus: a meta-analysis |
| Q37881950 | Attitudes of health care professionals toward pharmacogenetic testing |
| Q38651981 | Bayesian analysis of genetic association across tree-structured routine healthcare data in the UK Biobank |
| Q49612005 | Benefit of pre-emptive pharmacogenetic information on clinical outcome. |
| Q43274977 | Beyond debacle and debate: developing solutions in drug safety |
| Q38155921 | Bioactivation of drugs in the skin: relationship to cutaneous adverse drug reactions |
| Q28652448 | Biobanks and electronic medical records: enabling cost-effective research |
| Q47928481 | Biomarkers of adverse drug reactions. |
| Q57163738 | Biomarkers of drug-induced liver injury: progress and utility in research, medicine, and regulation |
| Q38194173 | Biomarkers: refining diagnosis and expediting drug development - reality, aspiration and the role of open innovation |
| Q30699715 | Bringing clinical pharmacogenomics information to pharmacists: A qualitative study of information needs and resource requirements |
| Q51599376 | CARD14 mutations may predict response to antitumour necrosis factor-α therapy in psoriasis: a potential further step towards personalized medicine. |
| Q36930041 | CYP2C19 drug-drug and drug-gene interactions in ED patients |
| Q41048998 | Can antiretroviral therapy be tailored to each human immunodeficiency virus-infected individual? Role of pharmacogenomics |
| Q38415606 | Can genomic medicine improve financial sustainability of health systems? |
| Q34598487 | Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations. |
| Q35447163 | Cardiovascular pharmacogenomics |
| Q38169969 | Cardiovascular pharmacogenomics: expectations and practical benefits |
| Q36487290 | Cardiovascular pharmacogenomics: the future of cardiovascular therapeutics? |
| Q28533795 | Case definitions, diagnostic algorithms, and priorities in encephalitis: consensus statement of the international encephalitis consortium |
| Q21563496 | Chapter 7: Pharmacogenomics |
| Q46847041 | Characterisation of the HLA-DRB1*07:01 biomarker for lapatinib-induced liver toxicity during treatment of early-stage breast cancer patients with lapatinib in combination with trastuzumab and/or taxanes |
| Q37287431 | Chemical individuality: concept and outlook |
| Q41045235 | Classifying ADRs--does dose matter? |
| Q40117884 | Clinical Abacavir Hypersensitivity Reaction among Children in India |
| Q37155053 | Clinical Application of Pharmacogenetics: Where are We Now? |
| Q39013613 | Clinical and regulatory considerations in pharmacogenetic testing. |
| Q36441517 | Clinical application of high throughput molecular screening techniques for pharmacogenomics |
| Q35502326 | Clinical applications of drug desensitization in the Asia-Pacific region |
| Q38654435 | Clinical characteristics and treatment outcome of Stevens-Johnson syndrome and toxic epidermal necrolysis |
| Q37678037 | Clinical implementation of genetic testing in medicine: a US regulatory science perspective |
| Q37775523 | Clinical implications of new findings in HIV basic research |
| Q36630680 | Clinical perspectives on human genetic screening to prevent nevirapine toxicity |
| Q36029478 | Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing |
| Q38541809 | Clinical pharmacokinetics and pharmacodynamics of dolutegravir used as a single tablet regimen for the treatment of HIV-1 infection |
| Q34736194 | Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America |
| Q37784777 | Clinical syndromes and consequences of antiretroviral-related hepatotoxicity |
| Q24657536 | Clinical use of pharmacogenomic tests in 2009 |
| Q35126221 | Closing the gap between knowledge and clinical application: challenges for genomic translation |
| Q24200188 | Co-formulated abacavir-lamivudine-zidovudine for initial treatment of HIV infection and AIDS |
| Q38367106 | Combination dolutegravir-abacavir-lamivudine in the management of HIV/AIDS: clinical utility and patient considerations |
| Q35889793 | Comparative Analysis of Real-Time Polymerase Chain Reaction Methods to Typing HLA-B*57:01 in HIV-1-Positive Patients. |
| Q41078615 | Comparative analysis between saliva and buccal swabs as source of DNA: lesson from HLA-B*57:01 testing. |
| Q36282969 | Comparison of HLA allelic imputation programs. |
| Q36762374 | Comprehensive genome-wide evaluation of lapatinib-induced liver injury yields a single genetic signal centered on known risk allele HLA-DRB1*07:01. |
| Q38779627 | Consolidation of molecular testing in clinical virology |
| Q38182188 | Contributions of pharmacogenetics and transcriptomics to the understanding of the hypersensitivity drug reactions |
| Q90678926 | Controversies in drug allergy: Testing for delayed reactions |
| Q40381501 | Correlation, in previously treated HIV-1 positive patients, between hypersensitivity reaction to abacavir and the presence of the HLA-B*5701 allele |
| Q42243458 | Cost impact of prospective HLA-B*5701-screening prior to abacavir/lamivudine fixed dose combination use in Germany |
| Q48314103 | Cost-effectiveness of HLA-DQB1/HLA-B pharmacogenetic-guided treatment and blood monitoring in US patients taking clozapine. |
| Q38671676 | Cost-effectiveness of pharmacogenetic-guided treatment: are we there yet? |
| Q37202607 | Creating and evaluating genetic tests predictive of drug response |
| Q58774245 | Critical assessment of approaches for molecular docking to elucidate associations of HLA alleles with adverse drug reactions |
| Q90859692 | Cross-ethnicity tagging SNPs for HLA alleles associated with adverse drug reaction |
| Q37394799 | Current concepts of mechanisms in drug-induced hepatotoxicity |
| Q34996898 | Current progress in pharmacogenetics. |
| Q43611334 | Current situation of the pharmacogenetics of immune recovery in treated HIV-infected patients |
| Q37293999 | Current trends in screening across ethnicities for hypersensitivity to abacavir |
| Q42132518 | Cutaneous drug hypersensitivity: immunological and genetic perspective |
| Q36059568 | Cutaneous side effects of antiosteoporosis treatments |
| Q36885006 | DILI: New Insights into Diagnosis and Management |
| Q92190152 | Dapsone- and nitroso dapsone-specific activation of T cells from hypersensitive patients expressing the risk allele HLA-B*13:01 |
| Q91016148 | Defining Regional Differences in Drug-Induced Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: A Tool to Improve Drug Safety? |
| Q57745295 | Deflating the Genomic Bubble |
| Q91126892 | Demonstrating Heterogeneity of Treatment Effects Among Patients: An Overlooked but Important Step Toward Precision Medicine |
| Q30758299 | Detection of HLA-B*57:01 by real-time PCR: implementation into routine clinical practice and additional validation data |
| Q50624617 | Detection of Primary T Cell Responses to Drugs and Chemicals in HLA-Typed Volunteers: Implications for the Prediction of Drug Immunogenicity. |
| Q33730146 | Developing pharmacogenetic evidence throughout clinical development |
| Q64938049 | Developing pharmacogenetic screening methods for an emergent country: Vietnam. |
| Q42607208 | Developing the evidence base for applying pharmacogenomics: proceeds from DIA Workshop IV--Breakout Session 1. |
| Q40405160 | Development of a simple genotyping method for the HLA-A*31:01-tagging SNP in Japanese |
| Q42213787 | Development of multiplex pyrosequencing for HLA-B*57:01 screening using single nucleotide polymorphism haplotype |
| Q91639512 | Development of the PGx-Passport: A Panel of Actionable Germline Genetic Variants for Pre-Emptive Pharmacogenetic Testing |
| Q90224362 | Diabetes: Is There a Future for Pharmacogenomics Guided Treatment? |
| Q47569828 | Diagnosing and managing patients with drug hypersensitivity |
| Q38222509 | Diagnostic accuracy of HLA-B*57:01 screening for the prediction of abacavir hypersensitivity and clinical utility of the test: a meta-analytic review |
| Q64126362 | Different roads, same destination |
| Q41747771 | Direct PCR: a new pharmacogenetic approach for the inexpensive testing of HLA-B*57:01. |
| Q37736460 | Direct-to-consumer genome testing: opportunities for pharmacogenomics research? |
| Q38097535 | Disclosure of individual pharmacogenomic results in research projects: when and what kind of information to return to research participants |
| Q38871356 | Distribution of HLA-B alleles in a Ugandan HIV-infected adult population: NORA pharmacogenetic substudy of DART. |
| Q37948858 | Do genome-wide association scans have potential for translation? |
| Q47603763 | Dolutegravir-induced liver injury leading to sub-acute liver failure requiring transplantation: a case report and review of literature. |
| Q43059203 | Dosing tacrolimus based on CYP3A5 genotype: will it improve clinical outcome? |
| Q44842257 | Drug Hypersensitivity and Anaphylaxis in Cancer and Chronic Inflammatory Diseases: The Role of Desensitizations |
| Q33839145 | Drug Hypersensitivity and Desensitizations: Mechanisms and New Approaches |
| Q55564369 | Drug Induced Hypersensitivity and the HLA Complex. |
| Q37349861 | Drug development: assessment of pharmacogenetic studies by Spanish research ethics committees |
| Q27679355 | Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire |
| Q35094201 | Drug hypersensitivity in human immunodeficiency virus-infected patient: challenging diagnosis and management |
| Q89885623 | Drug hypersensitivity reactions in Asia: regional issues and challenges |
| Q34701492 | Drug hypersensitivity: pharmacogenetics and clinical syndromes |
| Q64241592 | Drug reaction with eosinophilia and systemic symptoms (DRESS) in children |
| Q92535756 | Drug-Induced Liver Injury: Biomarkers, Requirements, Candidates, and Validation |
| Q33755165 | Drug-Induced Liver Injury: Cascade of Events Leading to Cell Death, Apoptosis or Necrosis |
| Q52346835 | Drug-Induced Skin Adverse Reactions: The Role of Pharmacogenomics in Their Prevention. |
| Q36512441 | Drug-induced arrhythmia: pharmacogenomic prescribing? |
| Q39887958 | Drug-induced hypersensitivity reactions and pharmacogenomics: past, present and future |
| Q37867695 | Drug-induced liver injury: a summary of recent advances. |
| Q35210890 | Drug-induced liver injury: the dawn of biomarkers? |
| Q37510856 | Drug-induced liver injury: what was new in 2008? |
| Q38122461 | Drug-reaction eosinophilia and systemic symptoms and drug-induced hypersensitivity syndrome |
| Q38554604 | Dual antiviral therapy for HIV and hepatitis C - drug interactions and side effects. |
| Q38736789 | Early gene expression changes with rush immunotherapy |
| Q42665272 | Economic efficiency of genetic screening to inform the use of abacavir sulfate in the treatment of HIV. |
| Q38095232 | Effect of the UGT1A1*28 allele on unconjugated hyperbilirubinemia in HIV-positive patients receiving Atazanavir: a systematic review |
| Q46488949 | Efficacy and tolerability of darunavir/ritonavir in combination with abacavir/lamivudine: an option in selected HIV-infected patients |
| Q41696314 | Efficacy of switching to dolutegravir plus rilpivirine, the small-tablet regimen, in patients with dysphagia: two case reports |
| Q34976470 | Epidemiology and risk factors for drug allergy |
| Q37540608 | Essential elements of personalized medicine |
| Q36605131 | Establishing the characteristics of an effective pharmacogenetic test for clozapine-induced agranulocytosis |
| Q51620356 | Estimation strategies for reacting to the identification of an association between the genome and adverse drug reactions. |
| Q64126594 | Evaluation of Prospective HLA-B*13:01 Screening to Prevent Dapsone Hypersensitivity Syndrome in Patients With Leprosy |
| Q41057427 | Evaluation of cytokine profile and HLA association in benznidazole related cutaneous reactions in patients with Chagas disease. |
| Q34002440 | Evaluation of drug interactions in a large sample of psychiatric inpatients: a data interface for mass analysis with clinical decision support software |
| Q49909599 | Evaluation of immune-mediated idiosyncratic drug toxicity using chimeric HLA transgenic mice. |
| Q93080606 | Evidence to Support Inclusion of Pharmacogenetic Biomarkers in Randomised Controlled Trials |
| Q26800980 | Evolving models of the immunopathogenesis of T cell-mediated drug allergy: The role of host, pathogens, and drug response. |
| Q28648163 | Extracting research-quality phenotypes from electronic health records to support precision medicine |
| Q27692095 | Fever, rash, and systemic symptoms: understanding the role of virus and HLA in severe cutaneous drug allergy. |
| Q42278364 | Flow cytometry analysis with a new FITC-conjugated monoclonal antibody-3E12 for HLA-B*57:01 rapid screening in prevention of abacavir hypersensitivity in HIV-1-infected patients |
| Q52660415 | Frank Stinchfield Award: Identification of the At-risk Genotype for Development of Pseudotumors Around Metal-on-metal THAs. |
| Q33775397 | French 2013 guidelines for antiretroviral therapy of HIV-1 infection in adults |
| Q43453078 | Frequencies of immune hypersensitivity reaction-associated HLA class I alleles in healthy South African Indian and mixed ancestry populations determined by a novel real-time PCR assay. |
| Q35179761 | Frequency of HLA B*5701 allele carriers in abacavir treated-HIV infected patients and controls from northeastern Brazil |
| Q37806982 | From evidence based medicine to mechanism based medicine. Reviewing the role of pharmacogenetics |
| Q83509385 | From evidence based medicine to mechanism based medicine. Reviewing the role of pharmacogenetics |
| Q61639626 | Genetic Basis of Delayed Hypersensitivity Reactions to Drugs in Jewish and Arab Populations |
| Q90379501 | Genetic Diversity of HLA Class I and Class II Alleles in Thai Populations: Contribution to Genotype-Guided Therapeutics |
| Q41389082 | Genetic Factors Influencing Drug-Induced Liver Injury: Do They Have a Role in Prevention and Diagnosis? |
| Q26768628 | Genetic Markers of the Host in Persons Living with HTLV-1, HIV and HCV Infections |
| Q52588359 | Genetic Testing in Clinical Settings. |
| Q37931275 | Genetic association studies in drug-induced liver injury |
| Q37389496 | Genetic association studies to detect adverse drug reactions: abacavir hypersensitivity as an example |
| Q89747408 | Genetic associations with clozapine-induced myocarditis in patients with schizophrenia |
| Q38095989 | Genetic characterization to improve interpretation and clinical management of hepatotoxicity caused by tyrosine kinase inhibitors. |
| Q37264559 | Genetic factors that confer sensitivity to HAART in HIV-infected subjects: implication of a benefit of an earlier initiation of HAART. |
| Q89155792 | Genetic markers of severe cutaneous adverse reactions |
| Q34389768 | Genetic screening for metabolic and age-related complications in HIV-infected persons |
| Q24202114 | Genetic testing for prevention of severe drug-induced skin rash |
| Q37430324 | Genetic tests and genomic biomarkers: regulation, qualification and validation |
| Q34072196 | Genetic variants of APOC3 promoter and HLA-B genes in an HIV infected cohort in northern South Africa: a pilot study |
| Q34400003 | Genetic variations in GRIA1 on chromosome 5q33 related to asparaginase hypersensitivity |
| Q33693846 | Genetic-based prediction of disease traits: prediction is very difficult, especially about the future |
| Q37396981 | Genetics and the general physician: insights, applications and future challenges |
| Q38207944 | Genetics of immune-mediated adverse drug reactions: a comprehensive and clinical review |
| Q37714294 | Genome-wide association studies in pharmacogenomics. |
| Q35288691 | Genome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocols |
| Q50680426 | Genomic medicine implementation: learning by example. |
| Q38114005 | Genomic medicine: a decade of successes, challenges, and opportunities |
| Q40086462 | Genomic testing as a tool to optimise drug therapy |
| Q35252277 | Genomics and drug response |
| Q36393911 | Genotype-based clinical trials in cardiovascular disease |
| Q38233757 | Genotype-guided drug prescribing: a systematic review and meta-analysis of randomized control trials |
| Q33582530 | Genotyping for severe drug hypersensitivity |
| Q96341703 | Global frequencies of clinically important HLA alleles and their implications for the cost-effectiveness of preemptive pharmacogenetic testing |
| Q43500764 | Guidance for pharmacogenomic biomarker testing in labels of FDA-approved drugs |
| Q22241321 | HIV Treatment Adherence, Drug Resistance, Virologic Failure: Evolving Concepts |
| Q83813731 | HIV as a chronic disease |
| Q58085173 | HIV control: Is getting there the same as staying there? |
| Q57096915 | HIV infection |
| Q40628462 | HIV infection : Test and treatment |
| Q37988776 | HIV therapies and the kidney: some good, some not so good? |
| Q37272625 | HLA B*5701 status, disease progression, and response to antiretroviral therapy |
| Q37963995 | HLA alleles and drug hypersensitivity reactions |
| Q37444410 | HLA and infectious diseases |
| Q38037649 | HLA and pharmacogenetics of drug hypersensitivity. |
| Q33666857 | HLA associations and clinical implications in T-cell mediated drug hypersensitivity reactions: an updated review. |
| Q47148549 | HLA genotyping by next-generation sequencing of complementary DNA. |
| Q50502052 | HLA polymorphisms influence the development of skin rash arising from treatment with EGF receptor inhibitors. |
| Q34172669 | HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans |
| Q34999573 | HLA-B allele and haplotype diversity among Thai patients identified by PCR-SSOP: evidence for high risk of drug-induced hypersensitivity |
| Q46238859 | HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis |
| Q93091889 | HLA-B*35:01 Allele Is a Potential Biomarker for Predicting Polygonum multiflorum-Induced Liver Injury in Humans |
| Q57273952 | HLA-B*38:02:01predicts carbimazole/methimazole-induced agranulocytosis |
| Q99608520 | HLA-B*39:01:01 is a novel risk factor for antithyroid drug-induced agranulocytosis in Japanese population |
| Q37667333 | HLA-B*57 Allele Is Associated with Concomitant Anti-tuberculosis and Antiretroviral Drugs Induced Liver Toxicity in Ethiopians |
| Q46445494 | HLA-B*5701 and hypersensitivity reactions to abacavir. Study methods and clinical relevance |
| Q42759515 | HLA-B*5701 frequency in Chilean HIV-infected patients and in general population |
| Q37514235 | HLA-B*5701 screening prior to abacavir prescription: clinical and laboratory aspects |
| Q33768961 | HLA-B*5701 testing to predict abacavir hypersensitivity |
| Q36343650 | HLA-B*57:01 allele prevalence in HIV-infected North American subjects and the impact of allele testing on the incidence of abacavir-associated hypersensitivity reaction in HLA-B*57:01-negative subjects |
| Q89997697 | HLA-B*57:01 allele prevalence in treatment-Naïve HIV-infected patients from Colombia |
| Q61447461 | HLA-B*57:01 screening and hypersensitivity reaction to abacavir between 1999 and 2016 in the OPERA observational database: a cohort study |
| Q91599524 | HLA-C*12:02 is strongly associated with Xuesaitong-induced cutaneous adverse drug reactions |
| Q52837404 | HLA-DQ allele-restricted activation of nitroso sulfamethoxazole-specific CD4-positive T lymphocytes from patients with cystic fibrosis. |
| Q47572304 | HLA-DQA1-HLA-DRB1 polymorphism is a major predictor of azathioprine-induced pancreatitis in patients with inflammatory bowel disease |
| Q42704205 | HLA-DQA1-HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants. |
| Q92432175 | HLA-DRB1*07:01 and lapatinib-induced hepatotoxicity: a systematic review and meta-analysis |
| Q47826173 | HLA-associated drug hypersensitivity and the prediction of adverse drug reactions. |
| Q38949927 | HLADR: a database system for enhancing the discovery of biomarkers for predicting human leukocyte antigen-mediated idiosyncratic adverse drug reactions. |
| Q47320133 | HLAs: Key regulators of T-cell-mediated drug hypersensitivity. |
| Q37635191 | Harms from medicines: inevitable, in error or intentional. |
| Q27335598 | Harvesting candidate genes responsible for serious adverse drug reactions from a chemical-protein interactome |
| Q48861311 | Health regulatory communications of well-established safety-related pharmacogenomics associations in six developed countries: an evaluation of alignment. |
| Q38542198 | Hepatotoxicity of New Oral Anticoagulants (NOACs). |
| Q95272476 | High-Resolution HLA Typing of HLA-A, -B, -C, -DRB1, and -DQB1 in Kinh Vietnamese by Using Next-Generation Sequencing |
| Q99711638 | High-Throughput Sequencing to Investigate Associations Between HLA Genes and Metamizole-Induced Agranulocytosis |
| Q33575664 | Host genetic determinants of human immunodeficiency virus infection and disease progression in children |
| Q36872470 | Host genomic influences on HIV/AIDS. |
| Q40097257 | Human Leukocyte Antigen (HLA) and Immune Regulation: How Do Classical and Non-Classical HLA Alleles Modulate Immune Response to Human Immunodeficiency Virus and Hepatitis C Virus Infections? |
| Q30238992 | Human leucocyte antigen-adverse drug reaction associations: from a perspective of ethnicity. |
| Q38285818 | Human leukocyte antigen genetic risk factors of drug-induced liver toxicology |
| Q41918861 | Hypersensitivity Reaction Associated with Abacavir Therapy in an Indian HIV Patient - A Case Report |
| Q34976463 | Hypersensitivity reactions to HIV therapy |
| Q58804798 | Hypertension genomics and cardiovascular prevention |
| Q92509274 | Identification of drug-specific public TCR driving severe cutaneous adverse reactions |
| Q37702844 | Identifying predictive markers for personalized treatment selection |
| Q83258983 | Identifying who is at risk of drug-induced liver injury: is human leukocyte antigen specificity the key? |
| Q26824391 | Idiosyncratic adverse drug reactions: current concepts |
| Q38145274 | Idiosyncratic drug-induced liver injury: an update on the 2007 overview |
| Q92377615 | Immune mechanisms of idiosyncratic drug-induced liver injury |
| Q37510953 | Immune mediation of hypersensitivity adverse drug reactions: implications for therapy |
| Q27681301 | Immune self-reactivity triggered by drug-modified HLA-peptide repertoire |
| Q63728479 | Immunity and mental illness: findings from a Danish population-based immunogenetic study of seven psychiatric and neurodevelopmental disorders |
| Q37786631 | Immunological aspects of nonimmediate reactions to beta-lactam antibiotics |
| Q37991389 | Immunomodulatory effects of antimicrobial agents. Part I: antibacterial and antiviral agents |
| Q26787099 | Impact of New Genomic Technologies on Understanding Adverse Drug Reactions |
| Q34147916 | Implementation and utilization of genetic testing in personalized medicine |
| Q39062032 | Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium. |
| Q39034897 | Implementing Precision Medicine: The Ethical Challenges |
| Q49999241 | Implementing pharmacogenomics decision support across seven European countries: The Ubiquitous Pharmacogenomics (U-PGx) project. |
| Q47274350 | Improved Diagnosis and Care for Rare Diseases through Implementation of Precision Public Health Framework |
| Q34316771 | In silico analysis of HLA associations with drug-induced liver injury: use of a HLA-genotyped DNA archive from healthy volunteers |
| Q54364218 | In the NEWS A QUICK ROUNDUP OF NEWS AND INFORMATION FROM OUR COMMUNITY. |
| Q26741420 | In vitro Models to Evaluate Drug-Induced Hypersensitivity: Potential Test Based on Activation of Dendritic Cells |
| Q39909074 | In vitro tests for drug hypersensitivity reactions: an ENDA/EAACI Drug Allergy Interest Group position paper |
| Q34484483 | Incidence and predictors of regimen-modification from first-line antiretroviral therapy in Thailand: a cohort study |
| Q39022892 | Incidence and risk estimate of drug-induced agranulocytosis in Hong Kong Chinese. A population-based case-control study. |
| Q89040497 | Increased risk of strontium ranelate-related SJS/TEN is associated with HLA |
| Q36441423 | Individualization of antiretroviral therapy |
| Q38040697 | Individualization of drug therapy: history, present state, and opportunities for the future |
| Q33443448 | Influence of human leukocyte antigen (HLA) alleles and killer cell immunoglobulin-like receptors (KIR) types on heparin-induced thrombocytopenia (HIT). |
| Q92320730 | Influence of tissue context on gene prioritization for predicted transcriptome-wide association studies |
| Q37715735 | Inhibition of human endogenous retrovirus-K by antiretroviral drugs |
| Q57415259 | Initiating allopurinol therapy: do we need to know the patient's human leucocyte antigen status? |
| Q36599112 | Integrating electronic health record genotype and phenotype datasets to transform patient care |
| Q37715400 | Integrating pharmacogenetic information and clinical decision support into the electronic health record |
| Q92102522 | Integrating pharmacogenetic testing into primary care |
| Q42672191 | Interethnic comparisons of important pharmacology genes using SNP databases: potential application to drug regulatory assessments |
| Q43447907 | Interlaboratory measurement differences in intracellular carbovir triphosphate concentrations in HIV-infected patients: sources of variability in processing, shipping, and quantitation |
| Q81236984 | Is personalized medicine finally arriving? |
| Q37500009 | Italian consensus statement on management of HIV-infected individuals with advanced disease naïve to antiretroviral therapy. |
| Q35567805 | Key role of human leukocyte antigen in modulating human immunodeficiency virus progression: An overview of the possible applications |
| Q38045377 | Latest advances in predicting DILI in human subjects: focus on biomarkers |
| Q42782253 | Learning from product labels and label changes: how to build pharmacogenomics into drug-development programs |
| Q37708018 | Leveraging Genomic Factors to Improve Benefit-Risk |
| Q36370325 | Leveraging genomic data in smoking cessation trials in the era of Precision Medicine: Why and how. |
| Q38852184 | Liver involvement in human immunodeficiency virus infection |
| Q36163437 | Looking to the future: incorporating genomic information into disparities research to reduce measurement error and selection bias |
| Q33779389 | Loss-of-function CYP2C9 variants: finding the correct clinical role for Type 2 diabetes pharmacogenetic testing |
| Q35977574 | Low prevalence of human leukocyte antigen-B*5701 in HIV-1-infected Chinese subjects: a prospective epidemiological investigation |
| Q35188723 | Management of HIV infection in treatment-naive patients: a review of the most current recommendations |
| Q57302639 | Mechanisms of Adverse Drug Reactions |
| Q34169362 | Mechanisms of drug-induced liver injury: from bedside to bench |
| Q64241600 | Mechanisms of hypersensitivity reactions induced by drugs |
| Q97549977 | Mechanistic insights into antiretroviral drug-induced liver injury |
| Q30808861 | Medical genomics: Gather and use genetic data in health care |
| Q47277590 | Medical histories |
| Q37937051 | Metabolic activation in drug-induced liver injury |
| Q37757136 | Methodological and statistical issues in pharmacogenomics |
| Q26744637 | MinION: A Novel Tool for Predicting Drug Hypersensitivity? |
| Q36426953 | Modifying Antiretroviral Therapy in Virologically Suppressed HIV-1-Infected Patients |
| Q36089652 | Molecular docking to identify associations between drugs and class I human leukocyte antigens for predicting idiosyncratic drug reactions. |
| Q38248679 | Molecular mechanisms for contribution of MHC molecules to autoimmune diseases |
| Q37617319 | Multiphenotype association study of patients randomized to initiate antiretroviral regimens in AIDS Clinical Trials Group protocol A5202. |
| Q36419326 | N-terminal valine adduct from the anti-HIV drug abacavir in rat haemoglobin as evidence for abacavir metabolism to a reactive aldehyde in vivo |
| Q44357874 | NAVAGATE: a rubric to move from pharmacogenomics science to pharmacogenomics practice |
| Q39533858 | NRTI backbone in HIV treatment: will it remain relevant? |
| Q33378483 | Natural variation in immune responses to neonatal Mycobacterium bovis Bacillus Calmette-Guerin (BCG) Vaccination in a Cohort of Gambian infants |
| Q35167944 | Nephrotoxicity of HAART |
| Q40092748 | Nevirapine patch testing in Thai human immunodeficiency virus infected patients with nevirapine drug hypersensitivity |
| Q47140255 | New Insights into Drug Reaction with Eosinophilia and Systemic Symptoms Pathophysiology |
| Q48012091 | New Rodent Population Models May Inform Human Health Risk Assessment and Identification of Genetic Susceptibility to Environmental Exposures |
| Q26800973 | New approaches for predicting T cell-mediated drug reactions: A role for inducible and potentially preventable autoimmunity |
| Q44117548 | New approaches to drug safety: a pharmacovigilance tool kit. |
| Q26800976 | New genetic findings lead the way to a better understanding of fundamental mechanisms of drug hypersensitivity |
| Q90334944 | New genetic predictors for abacavir tolerance in HLA-B*57:01 positive individuals |
| Q41876196 | Novel Concepts for Drug Hypersensitivity Based on the Use of Long-Time Scale Molecular Dynamic Simulation |
| Q64269386 | Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity |
| Q36173814 | Novel rare variants in congenital cardiac arrhythmia genes are frequent in drug-induced torsades de pointes. |
| Q44393316 | Novel sensitive, specific and rapid pharmacogenomic test for the prediction of abacavir hypersensitivity reaction: HLA-B*57:01 detection by real-time PCR. |
| Q92953588 | Older HIV-infected adults. Complex patients (III): Polypharmacy |
| Q36477760 | Omics Screening for Pharmaceutical Efficacy and Safety in Clinical Practice |
| Q39644558 | On pharmacogenomics in pharmacy benefit management |
| Q34976284 | Once-Daily, Single-Tablet Regimens For the Treatment of HIV-1 Infection |
| Q46544844 | Once-daily abacavir/lamivudine and ritonavir-boosted atazanavir for the treatment of HIV-1 infection in antiretroviral-naïve patients: a 48-week pilot study |
| Q88487480 | Opportunities and Challenges in Cardiovascular Pharmacogenomics: From Discovery to Implementation |
| Q37202877 | Optimizing drug outcomes through pharmacogenetics: a case for preemptive genotyping |
| Q37100793 | Other side of the coin for personalised medicine and healthcare: content analysis of 'personalised' practices in the literature |
| Q41505058 | Paediatric European Network for Treatment of AIDS (PENTA) guidelines for treatment of paediatric HIV-1 infection 2015: optimizing health in preparation for adult life |
| Q35219662 | Paediatric drug development: are population models predictive of pharmacokinetics across paediatric populations? |
| Q36417380 | Parsing interindividual drug variability: an emerging role for systems pharmacology |
| Q26784638 | Pathogenesis and diagnosis of delayed-type drug hypersensitivity reactions, from bedside to bench and back |
| Q38546782 | Pathogenesis of drug allergy--current concepts and recent insights |
| Q49617664 | Patient ethnicity and the risk of immune-mediated adverse drug reactions. |
| Q37816389 | Pediatric antiretroviral therapy |
| Q64241572 | Pediatric drug hypersensitivity: which diagnostic tests? |
| Q40149092 | Penicillin Allergy Is Not Necessarily Forever. |
| Q24339559 | Peptide-binding motifs and characteristics for HLA -B*13:01 molecule |
| Q34772602 | Perceptions of genetic testing and genomic medicine among drug users |
| Q64354468 | Personalised Medicine: The Odyssey from Hope to Practice |
| Q87675152 | Personalised medicine, disease prevention, and the inverse care law: more harm than benefit? |
| Q38976521 | Personalized learning: From neurogenetics of behaviors to designing optimal language training |
| Q42793934 | Personalized medicine and tobacco-related health disparities: is there a role for genetics? |
| Q57223243 | Personalized medicine for HLA-associated drug-hypersensitivity reactions |
| Q44620260 | Personalized medicine in sepsis: the coming of age. |
| Q36336007 | Personalized medicine: is it a pharmacogenetic mirage? |
| Q35107992 | Personalized sequencing and the future of medicine: discovery, diagnosis and defeat of disease. |
| Q39190869 | Personalizing carbamazepine therapy |
| Q34938911 | Personalizing health care: feasibility and future implications |
| Q38731079 | Personalizing supportive care in oncology patients using pharmacogenetic-driven treatment pathways |
| Q35895922 | Perspective: Does personalized medicine hold the future for medicine? |
| Q26853274 | Perspectives on pharmacogenomics of antiretroviral medications and HIV-associated comorbidities |
| Q33819062 | PharmGKB summary: abacavir pathway |
| Q35168561 | PharmGKB summary: very important pharmacogene information for human leukocyte antigen B. |
| Q92410147 | Pharmacist-Initiated Pre-Emptive Pharmacogenetic Panel Testing with Clinical Decision Support in Primary Care: Record of PGx Results and Real-World Impact |
| Q58799157 | Pharmacogenetic Markers of Drug Hypersensitivity in a Thai Population |
| Q97883055 | Pharmacogenetic Testing for Prevention of Severe Cutaneous Adverse Drug Reactions |
| Q35812195 | Pharmacogenetic allele nomenclature: International workgroup recommendations for test result reporting. |
| Q38214388 | Pharmacogenetic biomarkers for predicting drug response. |
| Q100723198 | Pharmacogenetic information in Swiss drug labels - a systematic analysis |
| Q38391340 | Pharmacogenetic testing in idiosyncratic drug-induced liver injury: current role in clinical practice |
| Q57475451 | Pharmacogenetic testing in oncology: a Brazilian perspective |
| Q33815409 | Pharmacogenetic testing through the direct-to-consumer genetic testing company 23andMe |
| Q37151528 | Pharmacogenetic testing: Current Evidence of Clinical Utility |
| Q37867481 | Pharmacogenetic testing: time for clinical practice guidelines |
| Q57302658 | Pharmacogenetic tests: the need for a level playing field |
| Q42965039 | Pharmacogenetics |
| Q47786696 | Pharmacogenetics and Pharmacogenomics in Moderate-to-Severe Psoriasis |
| Q37772183 | Pharmacogenetics and human genetic polymorphisms |
| Q44315373 | Pharmacogenetics and pharmacogenomics: adverse drug reactions |
| Q46402808 | Pharmacogenetics and rational drug use around the world |
| Q26797938 | Pharmacogenetics as a tool to tailor antiretroviral therapy: A review |
| Q40165805 | Pharmacogenetics at 50: genomic personalization comes of age. |
| Q34343365 | Pharmacogenetics in clinical practice: how far have we come and where are we going? |
| Q37275470 | Pharmacogenetics in drug discovery and development: a translational perspective |
| Q37532571 | Pharmacogenetics in heart failure: promises and challenges |
| Q37956206 | Pharmacogenetics in psychiatry: translating research into clinical practice. |
| Q37657531 | Pharmacogenetics in reproductive and perinatal medicine |
| Q64968253 | Pharmacogenetics in the Treatment of Cardiovascular Diseases and Its Current Progress Regarding Implementation in the Clinical Routine. |
| Q35840645 | Pharmacogenetics in type 2 diabetes: potential implications for clinical practice |
| Q57302675 | Pharmacogenetics of Adverse Drug Reactions |
| Q57302676 | Pharmacogenetics of Adverse Drug Reactions |
| Q36970927 | Pharmacogenetics of Potassium Channel Blockers |
| Q38221179 | Pharmacogenetics of antiretroviral therapy |
| Q37845914 | Pharmacogenetics of cutaneous adverse drug reactions |
| Q34118186 | Pharmacogenetics of drug hypersensitivity |
| Q37770487 | Pharmacogenetics of drug-induced liver injury |
| Q37969220 | Pharmacogenetics of drug-metabolizing enzymes: the prodrug hypothesis. |
| Q37107177 | Pharmacogenetics of hypersensitivity to abacavir: from PGx hypothesis to confirmation to clinical utility |
| Q37251569 | Pharmacogenetics of nucleoside reverse-transcriptase inhibitor-associated peripheral neuropathy |
| Q28083449 | Pharmacogenetics predictive of response and toxicity in acute lymphoblastic leukemia therapy |
| Q23919667 | Pharmacogenetics, pharmacogenomics, and individualized medicine |
| Q47776901 | Pharmacogenetics: a general review on progress to date |
| Q34171192 | Pharmacogenetics: from bench to byte--an update of guidelines |
| Q37430384 | Pharmacogenetics: implementing personalized medicine |
| Q52702236 | Pharmacogenomic Advances in the Prediction and Prevention of Cutaneous Idiosyncratic Drug Reactions. |
| Q47357309 | Pharmacogenomic Biomarkers for Improved Drug Therapy-Recent Progress and Future Developments |
| Q38364391 | Pharmacogenomic information in drug labels: European Medicines Agency perspective. |
| Q33910107 | Pharmacogenomic knowledge gaps and educational resource needs among physicians in selected specialties. |
| Q41764396 | Pharmacogenomic substudies of randomized controlled trials: consideration of safety outcomes. |
| Q35985374 | Pharmacogenomic test that predicts response to inhaled corticosteroids in adults with asthma likely to be cost-saving |
| Q46518961 | Pharmacogenomic testing and response to warfarin |
| Q92506521 | Pharmacogenomics |
| Q38607878 | Pharmacogenomics and Implications for Nursing Practice |
| Q37791154 | Pharmacogenomics and active surveillance for serious adverse drug reactions in children. |
| Q37658586 | Pharmacogenomics and patient care: one size does not fit all. |
| Q33762268 | Pharmacogenomics and personalized medicine: lost in translation? |
| Q38983589 | Pharmacogenomics and pharmacogenetics for the intensive care unit: a narrative review. |
| Q43450646 | Pharmacogenomics and the prevention of mother-to-child transmission of HIV. |
| Q64109702 | Pharmacogenomics in dermatology: tools for understanding gene-drug associations |
| Q28274686 | Pharmacogenomics in diabetes mellitus: insights into drug action and drug discovery |
| Q36001208 | Pharmacogenomics in early-phase clinical development |
| Q37933413 | Pharmacogenomics in the assessment of therapeutic risks versus benefits: inside the United States Food and Drug Administration |
| Q26782786 | Pharmacogenomics in the clinic |
| Q99630610 | Pharmacogenomics of COVID-19 therapies |
| Q35878413 | Pharmacogenomics of HIV therapy: summary of a workshop sponsored by the National Institute of Allergy and Infectious Diseases |
| Q27015820 | Pharmacogenomics of adverse drug reactions |
| Q34987138 | Pharmacogenomics of adverse drug reactions: practical applications and perspectives |
| Q34977413 | Pharmacogenomics of antimicrobial agents |
| Q30400366 | Pharmacogenomics of off-target adverse drug reactions |
| Q44807614 | Pharmacogenomics of severe cutaneous adverse reactions |
| Q34342305 | Pharmacogenomics of severe cutaneous adverse reactions and drug-induced liver injury |
| Q34976915 | Pharmacogenomics: the genetics of variable drug responses |
| Q37272534 | Pharmacogenomics: the promise of personalized medicine for CNS disorders. |
| Q37978619 | Pharmacogenomics: what is next? |
| Q38217626 | Pharmacogenovigilance: a pharmacogenomics pharmacovigilance program |
| Q28069383 | Pharmacokinetic, Pharmacogenetic, and Other Factors Influencing CNS Penetration of Antiretrovirals |
| Q43238013 | Pharmacology: A false sense of non-self |
| Q35408073 | Phenome-wide Association Study Relating Pretreatment Laboratory Parameters With Human Genetic Variants in AIDS Clinical Trials Group Protocols |
| Q38793657 | Phenome-wide scanning identifies multiple diseases and disease severity phenotypes associated with HLA variants. |
| Q34264876 | Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial |
| Q34806335 | Polymorphisms of Pyrimidine Pathway Enzymes Encoding Genes and HLA-B*40∶01 Carriage in Stavudine-Associated Lipodystrophy in HIV-Infected Patients |
| Q38051400 | Potential effect of pharmacogenetics on maternal, fetal and infant antiretroviral drug exposure during pregnancy and breastfeeding. |
| Q35604133 | Practical ethics: establishing a pathway to benefit for complex pharmacogenomic tests |
| Q47597667 | Practical recommendations for pharmacogenomics-based prescription: 2010 ESF-UB Conference on Pharmacogenetics and Pharmacogenomics |
| Q89658254 | Precision Medicine in Non-Communicable Diseases |
| Q39103035 | Precision medicine in allergic disease-food allergy, drug allergy, and anaphylaxis-PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma and Immunology |
| Q92838639 | Predicting (side) effects for patients with inflammatory bowel disease: The promise of pharmacogenetics |
| Q30793085 | Predicting HLA alleles from high-resolution SNP data in three Southeast Asian populations |
| Q37771029 | Predicting and preventing acute drug-induced liver injury: what's new in 2010? |
| Q38161564 | Prediction of hypersensitivity to antibiotics: what factors need to be considered? |
| Q44442043 | Predictive ability of direct-to-consumer pharmacogenetic testing: when is lack of evidence really lack of evidence? |
| Q38031096 | Predictive genetic testing for drug-induced liver injury: considerations of clinical utility |
| Q63241927 | Preempting and preventing drug-induced liver injury |
| Q101217454 | Prevalence and types of inconsistencies in clinical pharmacogenetic recommendations among major U.S. sources |
| Q37077485 | Prevalence of HLA-B*5701 and Its Relationship with Abacavir Hypersensitivity Reaction in Iranian HIV-Infected Patients |
| Q41000900 | Prevalence of HLA-B*57:01 allele in Argentinean HIV-1 infected patients |
| Q91655284 | Prevalence of abacavir-associated hypersensitivity syndrome and HLA-B*5701 allele in a Portuguese HIV-positive population |
| Q37638863 | Prevalence of human leukocyte antigen-B*5701 among HIV-infected children in Thailand and Cambodia: implications for abacavir use. |
| Q64285801 | Prevention and Diagnosis of Severe T-Cell-Mediated Adverse Drug Reactions: Are We There Yet? |
| Q28083100 | Progress in understanding the genomic basis for adverse drug reactions: a comprehensive review and focus on the role of ethnicity |
| Q37506497 | Promise of pharmacogenomics for drug discovery, treatment and prevention of Parkinson's disease. A perspective |
| Q37082500 | Promises and challenges of pharmacogenetics: an overview of study design, methodological and statistical issues |
| Q45966834 | Prospective-retrospective biomarker analysis for regulatory consideration: white paper from the industry pharmacogenomics working group. |
| Q38043095 | Prostate cancer: germline prediction for a commonly variable malignancy. |
| Q92642094 | Rapid Detection of HLA-B*57:01-Expressing Cells Using a Label-Free Interdigitated Electrode Biosensor Platform for Prevention of Abacavir Hypersensitivity in HIV Treatment |
| Q43734275 | Rapid screening for the detection of HLA-B57 and HLA-B58 in prevention of drug hypersensitivity |
| Q50071892 | Rare disease prevention and treatment: the need for a level playing field. |
| Q34131354 | Realities and expectations of pharmacogenomics and personalized medicine: impact of translating genetic knowledge into clinical practice |
| Q38753644 | Recent advances in biomarkers and therapeutic interventions for hepatic drug safety - false dawn or new horizon? |
| Q38931289 | Recent advances in the understanding of severe cutaneous adverse reactions |
| Q38457053 | Recent advances of pharmacogenomics in severe cutaneous adverse reactions: immune and nonimmune mechanisms |
| Q64061836 | Recent developments in genetic/genomic medicine |
| Q34408357 | Recommendations for HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions. |
| Q42366705 | Regional Experience of Abacavir: Valuable but Still has Unanswered Question. |
| Q57697208 | Removing barriers to a clinical pharmacogenetics service |
| Q34126724 | Renal function declines more in tenofovir- than abacavir-based antiretroviral therapy in low-body weight treatment-naïve patients with HIV infection |
| Q48160261 | Reply to: Medication contaminants as a potential cause of anaphylaxis to vincristine: What about drug specific antigens? |
| Q26800964 | Report from the National Institute of Allergy and Infectious Diseases workshop on drug allergy |
| Q42533914 | Responding to the clopidogrel warning by the US food and drug administration: real life is complicated |
| Q41756168 | Returning pharmacogenetic secondary findings from genome sequencing: let's not put the cart before the horse. |
| Q37871623 | Review article: Drug-induced liver injury--its pathophysiology and evolving diagnostic tools |
| Q35168108 | Risk factors for idiosyncratic drug-induced liver injury |
| Q37859373 | Risk modeling strategies for pharmacogenetic studies |
| Q38396234 | Role of dermatology in pharmacogenomics: drug-induced skin injury. |
| Q38941642 | Role of pharmacogenetics in public health and clinical health care: a SWOT analysis |
| Q35898538 | Role of the Pharmacist in Caring for Patients with HIV/AIDS: Clinical Practice Guidelines |
| Q50115047 | SJS/TEN 2017: Building Multidisciplinary Networks to Drive Science and Translation. |
| Q90466306 | SJS/TEN 2019: From science to translation |
| Q44483899 | Safe and effective medicines for all: is personalized medicine the answer? |
| Q34503452 | Safety analysis of Epzicom® (lamivudine/abacavir sulfate) in post-marketing surveillance in Japan |
| Q34503521 | Safety analysis of Ziagen® (abacavir sulfate) in postmarketing surveillance in Japan |
| Q42259925 | Safety and Efficacy of Ziagen (Abacavir Sulfate) in HIV-Infected Korean Patients |
| Q43027653 | Safety and efficacy of a 36-week induction regimen of abacavir/lamivudine and ritonavir-boosted atazanavir in HIV-infected patients |
| Q92649408 | Screening HLA to Prevent Severe Drug Reactions-A Devil's Advocate Perspective |
| Q88160211 | Severe Cutaneous Adverse Drug Reactions: Presentation, Risk Factors, and Management |
| Q28076600 | Severe Cutaneous Adverse Reactions: The Pharmacogenomics from Research to Clinical Implementation |
| Q39291741 | Severe Delayed Cutaneous and Systemic Reactions to Drugs: A Global Perspective on the Science and Art of Current Practice |
| Q41927200 | Severe Delayed Drug Reactions: Role of Genetics and Viral Infections. |
| Q55060097 | Severe cutaneous adverse reactions to drugs. |
| Q37992545 | Severe drug eruptions revisited |
| Q43118505 | Severe skin rash associated with atazanavir |
| Q91599716 | Single-Tablet Regimens in the Treatment of HIV-1 Infection |
| Q90415524 | Single-cell transcriptomics reveal polyclonal memory T-cell responses in skin with positive abacavir patch test results |
| Q35679980 | Smoking cessation pharmacogenetics: analysis of varenicline and bupropion in placebo-controlled clinical trials |
| Q35185164 | Statistical Optimization of Pharmacogenomics Association Studies: Key Considerations from Study Design to Analysis |
| Q38164730 | Stevens-Johnson syndrome / toxic epidermal necrolysis: an Asia-Pacific perspective |
| Q38689568 | Structural Elements Recognized by Abacavir-Induced T Cells |
| Q38080040 | Studies on abacavir-induced hypersensitivity reaction: a successful example of translation of pharmacogenetics to personalized medicine |
| Q33954585 | Successes achieved and challenges ahead in translating biomarkers into clinical applications |
| Q37436365 | Successful translation of pharmacogenetics into the clinic: the abacavir example |
| Q35737580 | Survival and HLA-B*57 in HIV/HCV Co-Infected Patients on Highly Active Antiretroviral Therapy (HAART). |
| Q37814401 | Systematic review of pharmacoeconomic studies of pharmacogenomic tests |
| Q79701040 | Systems biology and functional genomics approaches for the identification of cellular responses to drug toxicity |
| Q26824166 | Systems pharmacology: network analysis to identify multiscale mechanisms of drug action |
| Q34971993 | T cell-mediated hypersensitivity reactions to drugs |
| Q26747638 | T-cell-mediated drug hypersensitivity: immune mechanisms and their clinical relevance |
| Q53395242 | TNF-α genetic polymorphism -308G/A and antituberculosis drug-induced hepatitis. |
| Q47431684 | Tag SNPs for HLA-B alleles that are associated with drug response and disease risk in the Chinese Han population |
| Q37518294 | The 2013 Clinical Guidelines for the Diagnosis and Treatment of HIV/AIDS in HIV-Infected Koreans |
| Q26781379 | The 2015 Clinical Guidelines for the Diagnosis and Treatment of HIV/AIDS in HIV-Infected Koreans |
| Q64103074 | The 2018 Clinical Guidelines for the Diagnosis and Treatment of HIV/AIDS in HIV-Infected Koreans |
| Q38637036 | The 3 Cs of Antibiotic Allergy-Classification, Cross-Reactivity, and Collaboration |
| Q87796110 | The 8th International Congress on Cutaneous Adverse Drug Reactions, Taiwan, 2013: focus on severe cutaneous adverse reactions |
| Q39123582 | The Application of Genomics in Diabetes: Barriers to Discovery and Implementation |
| Q37776403 | The Application of Metabonomics to Predict Drug-Induced Liver Injury |
| Q93015537 | The Contribution of Major Histocompatibility Complex Class II Genes to an Association with Autoimmune Diseases |
| Q46442936 | The HCP5 single-nucleotide polymorphism: a simple screening tool for prediction of hypersensitivity reaction to abacavir |
| Q28080256 | The Importance of Patient-Specific Factors for Hepatic Drug Response and Toxicity |
| Q26772999 | The Need for Biomarkers in Diagnosis and Prognosis of Drug-Induced Liver Disease: Does Metabolomics Have Any Role? |
| Q36794572 | The Outlier in All of Us: Why Implementing Pharmacogenomics Could Matter for Everyone |
| Q28748224 | The application of mass-spectrometry-based protein biomarker discovery to theragnostics |
| Q38651282 | The chemical, genetic and immunological basis of idiosyncratic drug-induced liver injury. |
| Q37111658 | The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV. |
| Q59352293 | The dawn of precision medicine in HIV: state of the art of pharmacotherapy |
| Q38369889 | The emerging science of precision medicine and pharmacogenomics for Parkinson's disease |
| Q35023687 | The evolution of three decades of antiretroviral therapy: challenges, triumphs and the promise of the future. |
| Q38621727 | The evolving story of human leukocyte antigen and the immunogenetics of peanut allergy |
| Q38257150 | The first steps towards the era of personalised vaccinology: predicting adverse reactions |
| Q38773033 | The genetics of drug efficacy: opportunities and challenges |
| Q38040150 | The glory of guidelines and the twilight of reality: controversies and challenges in the prevention and treatment of HIV in children |
| Q89983773 | The hepatotoxicity of Polygonum multiflorum: The emerging role of the immune-mediated liver injury |
| Q38151546 | The impact of germline mutations on targeted therapy |
| Q64903516 | The impact of pharmacogenetics in the treatment of allergic disease and asthma. |
| Q37405140 | The impact of pharmacogenetics on HIV therapy |
| Q36441470 | The implications of pharmacogenomics in the treatment of HIV-1-infected patients of African descent. |
| Q37299239 | The medical and economic roles of pipeline pharmacogenetics: Alzheimer's disease as a model of efficacy and HLA-B(*)5701 as a model of safety |
| Q50504777 | The personalized medicine revolution: getting it right for children. |
| Q38088942 | The potential use of expression profiling: implications for predicting treatment response in rheumatoid arthritis |
| Q38075076 | The practice of pre-marketing safety assessment in drug development |
| Q84443544 | The promises of personalized medicine |
| Q38805500 | The purine analogues abacavir and didanosine increase acetaminophen-induced hepatotoxicity by enhancing mitochondrial dysfunction. |
| Q49356419 | The rise of the genome and personalised medicine. |
| Q39427540 | The role of HLA genes in pharmacogenomics: unravelling HLA associated adverse drug reactions |
| Q37430412 | The role of pharmacogenetics and pharmacogenomics in improving translational medicine. |
| Q38163945 | The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation. |
| Q34121303 | The rules remain the same for genomic medicine: the case against "reverse genetic exceptionalism". |
| Q38050483 | The structural basis of HLA-associated drug hypersensitivity syndromes |
| Q36203536 | The success of pharmacogenomics in moving genetic association studies from bench to bedside: study design and implementation of precision medicine in the post-GWAS era. |
| Q83005846 | The vaccine adverse event reporting system and vaccine safety research in the genomics era |
| Q43196823 | Thiopurine S- methyltransferase [corrected] testing in idiopathic pulmonary fibrosis: a pharmacogenetic cost-effectiveness analysis |
| Q28385221 | Tilting at quixotic trait loci (QTL): an evolutionary perspective on genetic causation |
| Q44684432 | Time (again) for a randomized trial of pharmacogenetics of antiretroviral therapy |
| Q33688133 | Towards the clinical implementation of pharmacogenetics in bipolar disorder. |
| Q38596576 | Toxic Epidermal Necrolysis Like Reaction due to Low-dose Methotrexate in a Case of Cutaneous Lupus Erythematosus: A Rare Occurrence |
| Q36954711 | Toxicity-related antiretroviral drug treatment modifications in individuals starting therapy: a cohort analysis of time patterns, sex, and other risk factors |
| Q34561910 | Toxicogenetics: population-based testing of drug and chemical safety in mouse models |
| Q38177342 | Toxicophores, reactive metabolites and drug safety: when is it a cause for concern? |
| Q35992621 | Translational research in infectious disease: current paradigms and challenges ahead |
| Q39712911 | Treating HIV-1 Infection: What Might the Future Hold? |
| Q37634509 | Treatment of HIV infection: Swedish recommendations 2009. |
| Q37634345 | Treatment of osteoporosis: recognizing and managing cutaneous adverse reactions and drug-induced hypersensitivity |
| Q44470116 | Trofile HIV co-receptor usage assay. |
| Q45919628 | Unboosted atazanavir plus co-formulated lamivudine/abacavir as a ritonavir-sparing simplification strategy in routine clinical practice. |
| Q36134088 | Understanding and predicting binding between human leukocyte antigens (HLAs) and peptides by network analysis |
| Q36085404 | Use of HLA-B*58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort study |
| Q34982530 | Use of biological knowledge to inform the analysis of gene-gene interactions involved in modulating virologic failure with efavirenz-containing treatment regimens in ART-naïve ACTG clinical trials participants. |
| Q37102523 | Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients |
| Q37264536 | Use of plasmid-derived external quality control samples in pharmacogenetic testing |
| Q57646588 | User considerations in assessing pharmacogenomic tests and their clinical support tools |
| Q37621615 | Using systems approaches to address challenges for clinical implementation of pharmacogenomics. |
| Q53135190 | Validation of a rapid test for HLA-B*58:01/57:01 allele screening to detect individuals at risk for drug-induced hypersensitivity. |
| Q37335127 | Vanishing bile duct and Stevens-Johnson syndrome associated with ciprofloxacin treated with tacrolimus |
| Q52927417 | Vertical Integration of Pharmacogenetics in Population PK/PD Modeling: A Novel Information Theoretic Method |
| Q30391322 | What's new for antiretroviral treatment in women with HIV |
| Q47744582 | Whole genome sequencing in critically ill children |
| Q57839685 | Whole-Genome Sequencing: The New Standard of Care? |
| Q37826340 | Why, when, and how should pharmacogenetics be applied in clinical studies?: current and future approaches to study designs |
| Q81743327 | [General concepts and study methods in pharmacogenetics] |
| Q83162303 | [HIV infection] |
| Q53782071 | [The HLA system in the Moroccan population: General review]. |
Search more.